Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P830055/S378

LCS Knee System

Depuy, Inc. · Decision date Oct 27, 2026

MEDTECHLEDGER EXPLANATIONP830055/S378

What did the FDA decide?

This 30-Day Notice for P830055/S378 records a process change at the DePuy Synthes manufacturing facility in Raynham, Massachusetts: introduction of an in-house X-ray inspection process. The device is the LCS® Knee System, classified as a semi-constrained, metal/polymer, mobile bearing patellofemorotibial knee prosthesis under product code NJL.

The supplement type is Process Change – Manufacturer/Sterilizer/Packager/Supplier, and the decision is OK30. The notice does not state what the X-ray inspection examines, which manufacturing steps it covers, or any resulting quality or safety outcomes. It is not a new approval of the knee system and does not establish clinical effectiveness.

FDA approval order statement

introduction of an in-house X-ray inspection process at DePuy Synthes manufacturing facility in Raynham, Massachusetts
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Orthopedic
Decision date
Oct 27, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P830055/S378
Regulatory pathway
PMA supplement
Applicant
Depuy, Inc.
Product code
NJL
Decision code
OK30
Decision date
Oct 27, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Prosthesis, knee, patellofemorotibial, semi-constrained, metal/polymer, mobile bearing.

Applicant
Depuy, Inc.
Product code
NJL
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P830055/S374 · Related supplement

    LCS(R) TOTAL KNEE SYSTEM, specifically ATTUNE Cruciate Retaining (CR), Posterior Stabilized (PS) and Revision Femoral C

  2. P830055/S372 · Related supplement

    ATTUNE Rotating Platform (RP) Total Knee System, ATTUNE Cementless Rotating Platform (RP) Knee System, ATTUNE Revision R

  3. P830055/S376 · Related supplement

    Attune Rotating Platform (RP) Total Knee System and the DePuy P.F.C. Sigma Rotating Platform (RP) Total Knee System an

  4. P830055/S351 · Related supplement

    Attune Revision Knee System

  5. P830055/S378 received

    Application receipt date recorded by FDA.

  6. P830055/S377 · Related supplement

    ATTUNE Rotating Platform (RP) Total Knee System, ATTUNE Revision Rotating Platform (RP) Total Knee System, and M.B.T. Re

  7. P830055/S379 · Related supplement

    ATTUNE Revision Knee System

  8. P830055/S381 · Related supplement

    ATTUNE Rotating Platform (RP) Total Knee System, and ATTUNE Revision Rotating Platform (RP) Knee System

  9. P830055/S378 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P830055. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P830055

Explore the linked device profile

Other records with product code NJL

Product / regulatory recordCompanyPathwayDecision dateSource
Zimmer, Inc.PMA supplementOct 16, 2026FDA
Zimmer, Inc.PMA supplementSep 24, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Depuy, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
P.O. Box 988, 700 Orthopaedic Dr., Warsaw, IN, 46581

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records